SynthesisFrontiers in research metrics and analytics2026
What evidence syntheses reveal about PROSPERO, INPLASY, OSF, the Research Registry, and protocols.io: a meta-research study.
Synthesis in Frontiers in research metrics and analytics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- How should retrospectively registered protocols be interpreted in systematic reviews?Systematic reviews · 2026Article
- Contemporary practices in scoping review protocol registration: a meta-research analysis of high-impact health journals (2024-2025).BMC medical research methodology · 2026Article
- Transparent qualitative model-building in high-stakes digital governance: a methods protocol for tracing institutional mechanisms.Frontiers in research metrics and analytics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This meta-research study examined how protocol registration information is reported in evidence syntheses published from 2020 to 2025 and registered in PROSPERO, INPLASY, OSF, the Research Registry, or protocols.io. Methods: We analyzed 4,750 studies covering various evidence synthesis types. Data were collected on registry use, reporting transparency, and accessibility features. Statistical comparisons included effect sizes with 95% confidence intervals. Results: PROSPERO remained the most widely used, with registrations from 70 countries. Among studies registered on non-PROSPERO platforms, more than 90% were found in INPLASY and OSF. Compared with PROSPERO, both registries demonstrated stronger reporting practices, with higher protocol status updates in INPLASY and more hyperlinks in OSF. However, a hyperlink did not always ensure public availability, as several OSF protocols required author authorization. Protocols in PROSPERO were associated with multiple publishers. In contrast, INPLASY protocols were more frequently linked to open-access journals, particularly those published by Frontiers and MDPI. Conclusion: Although PROSPERO remains the reference registry, INPLASY and OSF are playing an increasingly important role in promoting openness and accessibility. Researchers are encouraged to search multiple registries, especially PROSPERO, INPLASY, and OSF, before starting a new study to minimize the duplication of efforts. Systematic review registration: https://www.doi.org/10.37766/inplasy2025.6.0114, identifier INPLASY202560114.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.